Abstract
Cardiovascular disease is multidimensional and new ideas are needed to develop the conventional risk factor paradigm that has been based on the Framingham Heart Study since more than 30 years. Traditional risk factors such as hypertension, smoking, hyperlipidemia and diabetes can only explain about 50% of the distribution of coronary heart disease whereas the inclusion of new risk markers or protective markers may increase the explained proportion up to 80% of myocardial infarction risk according to the INTERHEART study. Still there are substantial differences in cardiovascular risk between regions and populations that are hard to explain. Findings in the former Soviet Union geographical area in Eastern Europe could contribute to new and better understanding of cardiovascular risk as a reflection of ageing in general, as populations in these areas not only run a very high cardiovascular risk but also have a shorter mean life expectancy in general. New understanding of the interaction between genes and the environment in prediction of cardiovascular ageing could contribute to the development of more effective preventive strategies.
Keywords: Ageing, cardiovascular, environment, genetic, Russia
Current Vascular Pharmacology
Title:Genetic and Environmental Determinants of Early Vascular Ageing (EVA)
Volume: 10 Issue: 6
Author(s): Peter M. Nilsson
Affiliation:
Keywords: Ageing, cardiovascular, environment, genetic, Russia
Abstract: Cardiovascular disease is multidimensional and new ideas are needed to develop the conventional risk factor paradigm that has been based on the Framingham Heart Study since more than 30 years. Traditional risk factors such as hypertension, smoking, hyperlipidemia and diabetes can only explain about 50% of the distribution of coronary heart disease whereas the inclusion of new risk markers or protective markers may increase the explained proportion up to 80% of myocardial infarction risk according to the INTERHEART study. Still there are substantial differences in cardiovascular risk between regions and populations that are hard to explain. Findings in the former Soviet Union geographical area in Eastern Europe could contribute to new and better understanding of cardiovascular risk as a reflection of ageing in general, as populations in these areas not only run a very high cardiovascular risk but also have a shorter mean life expectancy in general. New understanding of the interaction between genes and the environment in prediction of cardiovascular ageing could contribute to the development of more effective preventive strategies.
Export Options
About this article
Cite this article as:
M. Nilsson Peter, Genetic and Environmental Determinants of Early Vascular Ageing (EVA), Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520981
DOI https://dx.doi.org/10.2174/157016112803520981 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry Gender Related Issues in the Management of Heart Failure
Current Pharmaceutical Design Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Quantitative Analysis in Cardiovascular Imaging: Current Status
Current Medical Imaging The Patented Uses of D-Ribose in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design Valsartan Protects Against Contrast-Induced Acute Kidney Injury in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Apoptosis
Current Vascular Pharmacology Carotid Intima Media-thickness and Genes Involved in Lipid Metabolism in Diabetic Patients using Statins – a Pathway Toward Personalized Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Living Heart Valve and Small-Diameter Artery Substitutes - An Emerging Field for Intellectual Property Development
Recent Patents on Biotechnology Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Atrial Tachycardias Following Atrial Fibrillation Ablation
Current Cardiology Reviews MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Oxidative Stress in Atherosclerosis Development: The Central Role of LDL and Oxidative Burst
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Metabolomics
Current Drug Metabolism ACE2 and Diabetic Complications
Current Pharmaceutical Design